Monographie - Tigecycline

Última actualización :
18/04/2024

Tigecycline

Factores que influyen sobre la estabilidad

Estructura química

Nombre comercial

Los nombres comerciales son orientativos y los excipientes de la formulación pueden ser distintos dependiendo del país y del laboratorio fabricante.

Eticina	México
Grexyl	México
Linicetil	México
Mrsacin	Turquía
Tecygen	Chile
Tigecid	Turquía
Tigecilina	Argentina, Chile, Ecuador
Tigecycline	Canadá
Tigetop	Chile
Tizoxim	Argentina
Tygacil	Alemania, Arabia Saudita, Argentina, Austria, Bélgica, Canadá, Chile, Colombia, Dinamarca, Ecuador, Emiratos Árabes Unidos, España, Estados Unidos de América, Finlandia, Francia, Gran Bretaña, Grecia, Hungría, Irlanda, Islandia, Italia, Japón, Luxemburgo, Malasia, Marruecos, México, Noruega, Nueva Zelanda, Países Bajos, Polonia, Portugal, Rumania, Suecia, Suiza, Turquía, Venezuela
Zomiprerin	Marruecos

Bibliografía : Tigecycline

	Tipo	Publicación
2262	Periódico	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
3128	Laboratorio	Mitomycine (Amétycine®) - Résumé Caractéristiques du Produit Prostrakan 2013
3254	Periódico	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3332	Laboratorio	Tigecycline (Tigacyl®) - Summary of Product characteristics Pfizer 2012
3531	Laboratorio	Morphine sulphate 10 mg/mL injection BP – Summary of Product Characteristics Wockhardt 2014
3644	Laboratorio	Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010
3674	Laboratorio	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3827	Póster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Póster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Póster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3887	Periódico	Robiyanto R, Zaidi S.T.R, . Shastri M.D, Castelino R.L, Wanandy S.T, Jose M.D, . Patel R.P. Stability of Tigecycline in Different Types of Peritoneal Dialysis Solutions. Perit Dial Int 2016 ; 36:410-414.
4055	Periódico	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	Periódico	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4528	Periódico	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61

Mentions Légales